Biologically active insulin derivatives

The problem of insufficient stability and affinity of existing insulin analogs is solved by introducing additional covalent linkages between the insulin A and B chains, and its biological activity and therapeutic properties are improved.

CN118909079AInactive Publication Date: 2024-11-08CHEM & BIOPHARML LAB OF PATRAS
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410996682.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2013-12-05
Filing Date
2014-12-04
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing insulin analogs are blocked when binding to insulin receptors, resulting in reduced affinity and insufficient stability and solubility, affecting the therapeutic effect.

Method used

By introducing additional covalent linkages between the insulin A and B chains, additional bonds are formed using amino acid side chain functional groups, reducing chain flexibility and improving chemical stability while retaining bonds between chains to alleviate receptor binding resistance. The problem.

Benefits of technology

Improves the chemical stability and enzyme stability of insulin analogues, enhances its biological activity and therapeutic properties, and improves its affinity with insulin receptors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004960429640000011
    Figure BDA0004960429640000011
  • Figure BDA0004960429640000012
    Figure BDA0004960429640000012
  • Figure BDA0004960429640000081
    Figure BDA0004960429640000081
Patent Text Reader

Abstract

The present invention relates to insulin derivatives having biological activity. One aspect of the invention relates to single-chain insulin analogs comprising: (A) a chain A of human or animal insulin, or an analog or derivative thereof; (B) a B chain of human or animal insulin, or an analog or derivative thereof; (C) one or more disulfide bonds between the A chain and the B chain; and (D) another covalent linkage L between the functional group of the amino acid of the A chain and the functional group of the amino acid of the B chain, at least one of said functional groups being an amino acid side chain functional group. Another aspect of the invention relates to pharmaceutical compositions comprising said single-chain insulin derivatives, and therapeutic uses thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Single-chain insulin

    CN102816228A

  • Single chain insulin agonists exhibiting high activity at the insulin receptor

    CN103068842A

  • Single-chain insulin

    CN1902226A

  • Process for the preparation of insulin derivatives cross-linked by a dicarboxylic acid group at the amino a-1 glycine and amino b-29 lysine

    US3847893A

  • Ester insulin

    WO2011031662A1